Conley Chee - 11 Oct 2022 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Commercial Officer
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol
SYRS
Transactions as of
11 Oct 2022
Net transactions value
$0
Form type
4
Filing time
11 Oct 2022, 16:40:23 UTC
Previous filing
11 Oct 2022
Next filing
21 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Stock Option (right to buy) Award $0 +44,500 $0.000000 44,500 06 Oct 2022 Common Stock 44,500 $6.73 Direct F1
transaction SYRS Restricted Stock Units Award $0 +34,000 $0.000000 34,000 06 Oct 2022 Common Stock 34,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option becomes exercisable as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.
F2 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
F3 These RSUs will vest as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.

Remarks:

Exhibit 24: Power of Attorney